Want to see HK:6826 full AI Analyst Report?
Top Page
Shanghai Haohai Biological Technology Co., Ltd. Class H
(6826)
Select Model
Select Model
Rating:63Neutral
Price Target:
HK$17.50
▼(-29.72% Downside)
Action:Reiterated
Date:08/24/26
The score is primarily supported by balance-sheet strength and continued (though softer) positive cash generation, but is held back by weakening earnings/margins and below-long-term-trend technical positioning. A high dividend yield helps, while the elevated P/E reduces valuation support given the recent fundamental slowdown.
Positive Factors
Conservative balance sheet
Very low and stable leverage limits financial risk and preserves flexibility to fund research, capacity, or commercialization during a softer earnings period. The large equity base also provides resilience against operating volatility.
Negative Factors
Revenue contraction
Recent top-line contraction suggests weaker demand, product mix, or competitive conditions across the portfolio. Sustained revenue softness could constrain operating leverage, reduce resources for innovation, and make a return to prior profitability levels more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low and stable leverage limits financial risk and preserves flexibility to fund research, capacity, or commercialization during a softer earnings period. The large equity base also provides resilience against operating volatility.
Read all positive factors
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$7.42B
Dividend Yield5.83%
Average Volume (3M)132.16K
Price to Earnings (P/E)44.2
Beta (1Y)0.86
Revenue Growth-6.45%
EPS Growth-59.23%
CountryHK
Employees1,999
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.63
Shares Outstanding34,780,340
10 Day Avg. Volume121,120
30 Day Avg. Volume132,160
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)0.94
Price to Sales (P/S)2.08
P/FCF Ratio11.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.6
Revenue Forecast (FY)HK$2.61B
Shanghai Haohai Biological Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom,...
How the Company Makes Money
The company makes money primarily by selling proprietary medical devices and biomaterial-based products to healthcare providers and channel partners, generating revenue when products are delivered and accepted under customer contracts (exact reven...
Shanghai Haohai Biological Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
82
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.33B | 2.45B | 2.68B | 2.63B | 2.10B | 1.75B |
| Gross Profit | 1.52B | 1.69B | 1.87B | 1.85B | 1.45B | 1.26B |
| EBITDA | 189.94M | 418.16M | 549.05M | 713.41M | 447.55M | 550.45M |
| Net Income | 145.24M | 244.51M | 420.45M | 416.12M | 180.47M | 352.23M |
Balance Sheet | ||||||
| Total Assets | 6.56B | 6.72B | 7.12B | 7.11B | 6.89B | 6.95B |
| Cash, Cash Equivalents and Short-Term Investments | 2.40B | 2.52B | 2.76B | 2.75B | 2.56B | 2.91B |
| Total Debt | 443.14M | 398.67M | 448.43M | 407.95M | 118.26M | 105.51M |
| Total Liabilities | 1.09B | 1.12B | 1.20B | 1.09B | 990.02M | 890.07M |
| Stockholders Equity | 5.30B | 5.42B | 5.58B | 5.65B | 5.51B | 5.71B |
Cash Flow | ||||||
| Free Cash Flow | 260.48M | 446.40M | 283.08M | 367.22M | -85.85M | 70.19M |
| Operating Cash Flow | 498.64M | 628.50M | 648.57M | 634.45M | 231.30M | 342.29M |
| Investing Cash Flow | 35.84M | -10.81M | 282.28M | -376.65M | -681.82M | -148.09M |
| Financing Cash Flow | -420.39M | -509.70M | -390.35M | -257.73M | -288.35M | -231.25M |
Shanghai Haohai Biological Technology Co., Ltd. Class H Technical Analysis
Positive
24.90
Price Trends
16.15
Positive
17.31
Negative
20.61
Negative
Market Momentum
0.14
Negative
59.89
Neutral
71.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6826, the sentiment is Positive. The current price of 24.9 is above the 20-day moving average (MA) of 16.36, above the 50-day MA of 16.15, and above the 200-day MA of 20.61, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 59.89 is Neutral, neither overbought nor oversold. The STOCH value of 71.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6826.
Shanghai Haohai Biological Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$202.98B | 33.60 | 10.51% | ― | 21.93% | 21.94% | |
64 Neutral | HK$36.64B | 34.72 | 20.41% | ― | 32.63% | 8.87% | |
63 Neutral | HK$7.42B | 44.16 | 2.80% | 5.83% | -6.45% | -59.23% | |
62 Neutral | HK$73.73B | -13.67 | -16.23% | 0.35% | 53.48% | -120.02% | |
59 Neutral | HK$80.94B | 42.84 | 10.96% | 0.81% | 20.39% | 26.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$33.50B | -73.86 | -7.32% | ― | 34.83% | 58.94% |
* Healthcare Sector Average
HK:6826
Shanghai Haohai Biological Technology Co., Ltd. Class H
16.76
-9.99
-37.35%
HK:1548
Genscript Biotech
32.00
15.06
88.90%
HK:2269
Wuxi Biologics (Cayman)
47.50
11.50
31.94%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
28.28
5.76
25.55%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.14
-16.44
-48.96%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
64.50
-14.95
-18.82%
Shanghai Haohai Biological Technology Co., Ltd. Class H Corporate Events
Shanghai Haohai Biological Profit Slumps on Lower Revenue, Dividend Cut
Aug 21, 2026
Shanghai Haohai Biological Technology reported interim unaudited revenue of RMB1.17 billion for the six months ended 30 June 2026, down 9.81% from a year earlier. Net profit attributable to shareholders fell 46.64% to RMB112.63 million, while earn...
Shanghai Haohai Biological Declares 2026 Interim Dividend and Sets Payout Timetable
Aug 21, 2026
Shanghai Haohai Biological Technology has approved an interim dividend of RMB0.25 per share for the six months ended 30 June 2026, reflecting the board’s assessment of interim results and capital needs. After excluding treasury shares and re...
Shanghai Haohai Biotech Reshuffles Hong Kong Authorized Representatives
Aug 21, 2026
Shanghai Haohai Biological Technology Co., Ltd. has announced changes to its authorized representatives under Hong Kong listing rules. Non‑executive director Huang Ming will step down from the role, while executive director and joint company...
Shanghai Haohai Biological Declares Interim Dividend and Details Withholding Tax Rules
Aug 21, 2026
Shanghai Haohai Biological Technology has declared an interim ordinary cash dividend of RMB 0.25 per share for the six months ended 30 June 2026, payable in Hong Kong dollars at HKD 0.288995 per share. The dividend, relating to the financial year ...
Shanghai Haohai Sets August Board Meeting to Review Interim Results and Dividend
Aug 11, 2026
Shanghai Haohai Biological Technology Co., Ltd. has scheduled a board meeting for 21 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider the publication of these results and the...
Shanghai Haohai Clears Director Name Error as All AGM Resolutions Pass
May 29, 2026
Shanghai Haohai Biological Technology Co., Ltd. clarified that a typographical error had been made in previous documents regarding the English name of a nominated independent non-executive director, correcting it from Mr. Chan Sui Yu to Mr. Chan S...
Shanghai Haohai Overhauls Board Leadership and Committee Structure
May 29, 2026
Shanghai Haohai Biological Technology announced that executive director and chairman Dr. Hou Yongtai will resign from the board and its key committees, as well as from his role as the company’s legal representative, effective 29 May 2026 due...
Shanghai Haohai Biological Clarifies Board Composition and Committee Roles
May 29, 2026
Shanghai Haohai Biological Technology Co., Ltd. has disclosed the current composition of its board, comprising executive, non-executive, and independent non-executive directors, reflecting a diversified governance structure with staff representati...
Shanghai Haohai Biological Tech Sets Final 2025 Dividend and Payment Terms
May 29, 2026
Shanghai Haohai Biological Technology has declared a final ordinary dividend of RMB 0.6 per share for the financial year ended 31 December 2025, with shareholder approval obtained on 29 May 2026. For H-share investors in Hong Kong, the payout will...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.